CD19 and acute lymphoblastic leukemia: CD19 CAR studies in ALL have shown that while 4-1BB domain of FMC63-based CD19 CAR confers persistence, CD28 domain on an FMC-63-targeted CAR results in stronger and faster CAR activation and cytokine release, but also shorter persistence.